The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Δημοσίευση

The flipside of hydralazine in pregnancy: A systematic review and meta-analysis.

TitleThe flipside of hydralazine in pregnancy: A systematic review and meta-analysis.
Publication TypeJournal Article
Year of Publication2020
AuthorsAntza, C., Dimou C., Doundoulakis I., Akrivos E., Stabouli S., Haidich A. Bettina, Goulis D. G., & Kotsis V.
JournalPregnancy Hypertens
Volume19
Pagination177-186
Date Published2020 Jan
ISSN2210-7797
Abstract

The present systematic review and meta-analysis investigated the effects of hydralazine compared with other antihypertensive drugs in maternal, perinatal and neonatal outcomes of pregnant women with hypertensive disorders. Twenty studies with 1283 participants were included. Of them, 626 received hydralazine and 657 other antihypertensive treatments, such as labetalol, nifedipine, ketanserin, diazoxide, urapidil, isradipine and epoprostenol. Women receiving hydralazine had higher heart rate (WMD: 13.4, 95%CI: 0.1 to 26.8 beats/min), increased number of adverse effects (RR: 1.21, 95%CI: 1.01 to 1.45) and gave birth to neonates of lower birthweight (WMD: 13.4, 95%CI: 0.1 to 26.8 beats/min) compared with other antihypertensive treatments at the end of follow-up. When studies, which used antihypertensive agents that are no longer indicated for hypertension in pregnancy, were excluded in the sensitivity analyses, hydralazine found not to have a statistically significant difference compared with labetalol and nifedipine regarding the reduction of maternal blood pressure (WMD: 1.72, 95%CI: -1.47 to 4.9 mmHg for systolic, WMD: 0.26, 95%CI: -1.75 to 2.28 mmHg for diastolic), maternal heart rate (WMD: 13.56, 95%CI: -5.62 to 32.74 beats/min), low birthweight (WMD: -88.62, 95%CI: -243.24 to 66 beats/min) and adverse events (RR: 1.19, 95%CI: 0.99 to 1.43). Hydralazine seems not to be inferior compared to labetalol and nifedipine for safety and efficacy.

DOI10.1016/j.preghy.2020.01.011
Alternate JournalPregnancy Hypertens
PubMed ID32044579

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.